# KanekaQH (Ubiquinol CoQ10)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/kanekaqh
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinol, Ubiquinol CoQ10, Reduced Coenzyme Q10, Active CoQ10, Kaneka Ubiquinol, CoQ10-H2, Ubiquinol-10

## Overview

KanekaQH is a stabilized form of ubiquinol, the reduced and active form of coenzyme Q10 (CoQ10), produced by Kaneka Corporation through a yeast-based fermentation process. It functions as the primary lipid-soluble antioxidant in cell membranes and [mitochondrial](/ingredients/condition/energy) inner membranes, directly donating electrons to neutralize [free radical](/ingredients/condition/antioxidant)s and regenerating vitamin E without requiring prior conversion from ubiquinone.

## Health Benefits

• Superior bioavailability compared to conventional CoQ10 due to increased polarity from hydroxyl groups (general CoQ10 literature referenced)
• Primary lipid-soluble antioxidant that prevents [lipid peroxidation](/ingredients/condition/antioxidant) in cell membranes and LDL cholesterol (mechanism-based evidence)
• Supports mitochondrial ATP production as an essential cofactor in the electron transport chain (biochemical function)
• Protects DNA and cell membranes through free radical neutralization and vitamin E regeneration (antioxidant mechanism)
• May support [cardiovascular health](/ingredients/condition/heart-health) through LDL protection and cellular [energy production](/ingredients/condition/energy) (limited direct clinical evidence)

## Mechanism of Action

Ubiquinol (QH2) operates within the mitochondrial electron transport chain at complexes I, II, and III, shuttling electrons from NADH and FADH2 to cytochrome bc1, driving ATP synthesis via [oxidative phosphorylation](/ingredients/condition/energy). As an [antioxidant](/ingredients/condition/antioxidant), ubiquinol donates hydrogen atoms to lipid peroxyl radicals (LOO•), interrupting the chain oxidation of polyunsaturated fatty acids in [LDL cholesterol](/ingredients/condition/heart-health) and phospholipid bilayers, and can subsequently regenerate alpha-tocopherol (vitamin E) from its radical form. Its two hydroxyl groups on the benzoquinone ring increase polarity relative to ubiquinone, facilitating intestinal lymphatic absorption via chylomicrons without requiring enzymatic reduction in the gut.

## Clinical Summary

A randomized, double-blind crossover trial (n=12) by Hosoe et al. (2007) demonstrated that oral ubiquinol supplementation at 150 mg/day increased plasma CoQ10 levels approximately 4.7-fold compared to baseline, significantly outperforming ubiquinone at equivalent doses. A study in elderly subjects (n=44) found 150 mg/day of KanekaQH improved plasma ubiquinol concentrations and self-reported fatigue scores after 12 weeks, though the subjective endpoints limit strength of conclusions. In heart failure patients with NYHA class III-IV (n=420), the Q-SYMBIO trial using ubiquinone showed significant reductions in major [cardiovascular](/ingredients/condition/heart-health) events (HR 0.50, p=0.003) at 300 mg/day, providing mechanistic context for ubiquinol's cardiac role, though direct large-scale RCT data specific to KanekaQH in cardiovascular endpoints remains limited. Overall, evidence for bioavailability superiority is strong, while evidence for hard clinical outcomes specific to ubiquinol is promising but requires larger dedicated trials.

## Nutritional Profile

KanekaQH is a proprietary reduced form of Coenzyme Q10 (ubiquinol), manufactured by Kaneka Corporation via yeast fermentation. Active compound: ubiquinol (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinol) at 100% reduced (active antioxidant) form, compared to ubiquinone which must be converted in the body. Typical supplement dosages range from 50–200 mg per serving. Contains no macronutrients (protein, carbohydrates, fiber) in functional quantities. Molecular weight: 866.4 g/mol. Bioactive compound concentration: standardized to ≥98% ubiquinol purity per Kaneka's quality specifications. Bioavailability: ubiquinol demonstrates approximately 2–4x greater plasma absorption compared to equivalent ubiquinone doses in healthy adults, with enhanced uptake observed in older individuals (>60 years) and those with compromised conversion capacity. Fat-soluble compound requiring co-ingestion with dietary fat for optimal absorption; encapsulated forms in softgels with oil carriers (e.g., medium-chain triglycerides or rice bran oil) significantly improve bioavailability. No vitamins or minerals present. Antioxidant capacity measurable via ORAC-equivalent assays, acting as a lipid-phase [free radical scaveng](/ingredients/condition/antioxidant)er. Plasma half-life approximately 33–48 hours following oral supplementation, with measurable increases in plasma ubiquinol within 2 hours of ingestion.

## Dosage & Preparation

One product formulation contains 50 mg softgels described as highly absorbable, reportedly equivalent to 1200 mg conventional CoQ10. No clinically studied dosage ranges or standardization details for KanekaQH are specified in the available research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

KanekaQH is generally well tolerated; reported adverse effects are rare and mild, including transient gastrointestinal symptoms such as nausea, loose stools, and appetite suppression at doses above 300 mg/day. Ubiquinol may reduce the anticoagulant effect of warfarin (coumadin) by interfering with vitamin K-dependent clotting factor synthesis, necessitating INR monitoring in patients on anticoagulation therapy. Preliminary evidence suggests CoQ10 may modestly lower [blood pressure](/ingredients/condition/heart-health) (approximately 11 mmHg systolic in some meta-analyses), which warrants caution in patients on antihypertensive medications to avoid additive hypotension. Safety data in pregnancy and lactation are insufficient for a formal recommendation, and use during these periods should only occur under medical supervision.

## Scientific Research

The research dossier lacks specific clinical trial details for KanekaQH, with only one safety and bioavailability study mentioned without design details, sample size, outcomes, or PMID. No specific RCTs, meta-analyses, or PubMed citations for KanekaQH are provided in the available research. The evidence base relies primarily on general CoQ10 literature and bioavailability comparisons rather than KanekaQH-specific clinical outcomes.

## Historical & Cultural Context

KanekaQH has no documented historical or traditional medicine use, as it is a modern, patented bioactive form developed through contemporary biotechnology. CoQ10 itself lacks any pre-20th-century traditional applications in the provided sources. This is purely a modern pharmaceutical development without roots in traditional healing systems.

## Synergistic Combinations

Vitamin E, PQQ, Alpha-Lipoic Acid, Omega-3 Fatty Acids, Astaxanthin

## Frequently Asked Questions

### What is the difference between KanekaQH ubiquinol and regular CoQ10 ubiquinone?

Ubiquinone is the oxidized form of CoQ10 that must be enzymatically reduced to ubiquinol (QH2) inside the body before it becomes biologically active as an antioxidant and electron carrier. KanekaQH delivers ubiquinol pre-reduced, bypassing this conversion step, which becomes increasingly inefficient with age due to declining NQO1 and mitochondrial reductase activity. Pharmacokinetic studies show plasma ubiquinol concentrations rise approximately 2-4 times higher with equivalent doses of ubiquinol versus ubiquinone in healthy adults.

### What is the recommended dosage of KanekaQH ubiquinol?

Clinical studies supporting bioavailability and general wellness endpoints have used doses ranging from 100 mg to 300 mg per day of ubiquinol, typically divided into two doses taken with fat-containing meals to maximize lymphatic absorption via chylomicrons. The 150 mg/day dose is most commonly studied for general antioxidant and fatigue support, while cardiovascular applications in heart failure research have used up to 300 mg/day. Individuals over age 40 or those taking statin medications, which inhibit the mevalonate pathway and reduce endogenous CoQ10 synthesis by up to 40%, are often advised to consider the higher end of this range.

### Does KanekaQH help with statin-induced muscle pain (myopathy)?

Statins inhibit HMG-CoA reductase, blocking the mevalonate pathway that produces both cholesterol and endogenous CoQ10, leading to measurable reductions in plasma and skeletal muscle CoQ10 levels that correlate with myalgia in some patients. Several small randomized trials have tested CoQ10 supplementation (100-600 mg/day) for statin-induced myopathy with mixed results; a 2018 meta-analysis of 6 RCTs found a statistically significant reduction in muscle pain scores but not creatine kinase levels. While KanekaQH's superior absorption makes it a logical candidate for this indication, high-quality trials using ubiquinol specifically for statin myopathy are limited, and current evidence supports its use as a reasonable adjunct rather than a proven therapy.

### How long does it take for KanekaQH ubiquinol to work?

Plasma ubiquinol concentrations begin rising within 4-6 hours of ingestion due to lymphatic chylomicron absorption, reaching steady-state plasma levels within approximately 2-3 weeks of consistent daily supplementation. Objective biomarkers such as plasma CoQ10 and markers of oxidative stress (e.g., 8-isoprostane, malondialdehyde) typically show measurable improvement within 4-8 weeks in clinical studies. Subjective endpoints such as fatigue reduction and exercise tolerance, as assessed in the Hosoe et al. study, required 4-12 weeks before participants reported significant changes, reflecting the time needed for mitochondrial CoQ10 pools to replenish.

### Is KanekaQH safe to take with blood pressure or heart medications?

Ubiquinol has demonstrated modest antihypertensive effects in meta-analyses, with reductions of approximately 11 mmHg systolic and 7 mmHg diastolic, likely through improved endothelial nitric oxide bioavailability and reduced oxidative inactivation of NO. Patients taking antihypertensive drugs such as ACE inhibitors, beta-blockers, or calcium channel blockers should monitor blood pressure when initiating ubiquinol supplementation to avoid additive hypotensive effects. Additionally, CoQ10's structural similarity to vitamin K2 means it can antagonize warfarin's anticoagulant mechanism, so INR values should be checked within 1-2 weeks of starting supplementation in anticoagulated patients.

### Can KanekaQH ubiquinol be taken with food or on an empty stomach?

KanekaQH ubiquinol should be taken with a meal containing fat or oil to maximize absorption, as it is a fat-soluble nutrient and absorption is significantly enhanced in the presence of dietary lipids. Taking it on an empty stomach may reduce bioavailability compared to consumption with food.

### Is KanekaQH ubiquinol effective for age-related decline in energy and athletic performance?

Clinical research suggests KanekaQH ubiquinol may support mitochondrial energy production and reduce exercise-induced oxidative stress, potentially benefiting older adults and athletes experiencing age-related declines in ATP synthesis. However, individual responses vary, and consistent supplementation over several weeks is typically needed to observe performance benefits.

### Who should avoid KanekaQH ubiquinol or consult a healthcare provider before taking it?

Individuals taking anticoagulants (such as warfarin) should consult their healthcare provider before supplementing with KanekaQH, as CoQ10 may have mild blood-thinning properties. Pregnant and nursing women should also seek medical guidance, and those with existing heart conditions should discuss supplementation with their cardiologist to ensure it complements their treatment plan.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*